Aspen said it was “extremely disappointed” to learn over the past weekend that specific batches of the Johnson & Johnson (J&J) Covid-19 vaccine made at its Gqeberha production site, and destined for the South African market, had to be destroyed. This was because of the risk of isolated material in the drug substance supplied to Aspen by J&J from their contract manufacturing partner in the US, Emergent, Aspen said in a statement yesterday. The batches had been retained in storage awaiting the outcome of the US Food and Drug Administration’s assessment of Emergent. “This is not only a setback to both the Aspen and J&J teams who have worked tirelessly to ensure the manufacture of these batches, but, more importantly, has the potential to negatively impact the vaccine roll-out across…